Activating HER2 mutations and HER2 amplification are early events in breast tumorigenesis occurring in almost 50% of in situ carcinomas and, in 20% of the cases, are maintained during progression of the disease to the invasive type [36,64]. The gene discussed is ERBB2; the disease is in situ carcinoma.